AEGiS-IRIN: Zimbabwe: Another setback for anti-AIDS treatment UN Integrated Regional Information NetworkImportant note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Click here to return to UN Integrated Regional Information Network main menu
DonateNow


Zimbabwe: Another setback for anti-AIDS treatment

Integrated Regional Information Networks - December 14, 2006


[This report does not necessarily reflect the views of the United Nations]

BULAWAYO, 14 December (PLUSNEWS) - Zimbabwe's health minister, HIV/AIDS activists and health experts have all warned that a recent increase in the cost of CD4 tests, which measure the strength of the immune system, will negatively affect the already ailing national AIDS treatment programme.

The tests are essential to assess the degree to which an immune system has been compromised by the virus, and one of the most important tools for deciding when someone should begin antiretroviral (ARV) treatment. CD4 cell testing is also used to determine the efficacy of ARV therapy.

According to health minister David Parirenyatwa, the scarcity of testing centres in Zimbabwe has allowed the few available ones to charge astronomical fees. "Testing costs, especially at private health institutions, have soared of late. Many people cannot afford them, and this is a setback that has to be addressed as a matter of urgency," he said. "We have a situation whereby patients end up dying prematurely, just because they have taken antiretroviral (ARV) drugs without going through proper CD4 count tests first to ascertain their condition."

There are only two health facilities conducting CD4 count tests, both privately owned, in Bulawayo, Zimbabwe's second city, which has a population of almost 2 million. Both doubled their testing fees two weeks ago, from Z$25,000 (US$100) to Z$50,000 (US$200), sparking an outcry by AIDS activists.

"Patients normally start treatment when their CD4 count is below 200," said Ambivalence Dube, a Bulawayo-based AIDS activist and health expert. "However, with the recent increases, we are likely to see many people shying away from [CD4 count] testing, and this will negate the whole concept of fighting HIV/AIDS." Dube said many people who started taking ARVs without first ascertaining their CD4 count suffered complications.

The lack of testing centres in public health facilities has been blamed on government funding shortfalls. Privately owned testing centres have taken advantage of the gap in provision.

According to the National AIDS Council, set up by the government to combat the HIV/AIDS pandemic, at least 14,000 Zimbabweans die each month of AIDS-related illnesses. Experts attribute the high death rate to low nutritional levels and limited access to life-prolonging ARVs. As of July 2006, only 46,000 of the estimated 600,000 people in need of ARVs were receiving them in the national treatment programme.

UNAIDS estimates that Zimbabwe has the fourth highest level of HIV/AIDS prevalence in the world: in a population of 11.5 million, an estimated 20.1 percent of sexually active adults are HIV-infected.

Despite recent evidence of a decline in the infection rate, analysts have warned that with a crumbling health sector and an economy in the doldrums, Zimbabwe still has a long way to go before the fight against the epidemic is won.


061214
IR061227


Copyright © 2006 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980 – 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .